Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01766921 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase 2 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,393
- Enrollment target
NCT01766921 is a Phase 2 study that has completed, run by Novartis Vaccines. The registered enrollment target is 1,393 participants.
The verdict
NCT01766921, a Phase 2 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,393 participants
- Enrollment target
Study Summary
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects
Interventions
- BIOLOGICAL Adjuvanted H5N1 pandemic influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,393 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01766921
The ClinicalTrials.gov registry entry for NCT01766921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,393 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adjuvanted H5N1 pandemic influenza vaccine is the first listed.
NCT01766921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01766921 about?
NCT01766921 is a clinical study titled "Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects". Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects
What is the current status of trial NCT01766921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,393 participants. The study started on 2013-01. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01766921?
The interventions under investigation include: Adjuvanted H5N1 pandemic influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01766921?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.